...one USP into the clinic in that time frame. The fate of Hybrigenics Dutch subsidiary, Semaia...
...of the discarded discovery work, hangs in the balance. "We are currently looking at how Semaia...

...on signal transduction in cancer. "Semaia had been financed to the tune of about E Semaia's...
...to go," Strosberg said. Hybrigenics will use its technology to identify proteins that interact with Semaia's...
...cancers as well as viral diseases such as AIDS and hepatitis C. Rian De Jonge, Semaia's...

...Infectious diseases Hired: Rian De Jonge as executive vice president of R&D, formerly CEO of Semaia...

...Proteomics company Hybrigenics acquired Semaia, which focuses on signal transduction in cancer, in a stock deal...
...in cancer, in a stock deal. Hybrigenics will use its functional proteomics technology to prioritize Semaia's...
...Hybrigenics also will use its protein interaction mapping technology to identify proteins that interact with Semaia's...

...Proteomics company Hybrigenics (Paris, France) acquired Semaia (Utrecht, the Netherlands), which focuses on signal transduction in...
...in cancer, in a stock deal. Hybrigenics will use its functional proteomics technology to prioritize Semaia's...
...also will use its protein interaction mapping technology to identify other proteins that interact with Semaia's...

...to four new validated cancer disease targets from Semaia. Genmab A/S (CSE:GEN; NMarkt:GE9D), Copenhagen, Denmark Semaia...

...news it will develop and test new antibodies against up to four cancer targets from Semaia...

...develop and test new antibodies against up to four new validated cancer disease targets from Semaia...

...million ($1.8 million) grant to identify and validate proteins involved in the etiology of cancer. Semaia...